Abstracts tagged "Bisphosphonates"

Abstract Number: 1149 • ACR Convergence 2021
Efficacy of Alendronate for Prevention of New Fractures and Vertebral Deformities in Patients with Rheumatologic Disorders on Chronic Glucocorticoid Therapy: A Systematic Review and Meta-analysis
Saffa Iftikhar¹, Waleed Khokher², Ashu Acharya¹, Joan Gekonde³, Nithin Kesireddy², Rawish Fatima¹ and Nezam Altorok², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH, ³University of Toledo, Sylvania Township, OH
Background/Purpose: Glucocorticoids are commonly used in patients with rheumatologic conditions including but not limited to Rheumatoid Arthritis, Polymyalgia Rheumatica, Systemic Lupus Erythematous and so on.…
Abstract Number: 1875 • 2019 ACR/ARP Annual Meeting
Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
David Kendler¹, Arkadi Chines ², Patricia Clark ³, Peter R. Ebeling ⁴, Michael McClung ⁵, Yumie Rhee ⁶, Shuang Huang ², Robert Kees Stad ⁷ and Nick Freemantle ⁸, ¹University of British Columbia, Vancouver, BC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Hospital Infantil de Mexico Federico Gómez and National University of Mexico, Mexico City, Mexico, ⁴Monash University, Melbourne, Victoria, Australia, ⁵Oregon Osteoporosis Center, Portland, OR, ⁶Yonsei University College of Medicine, Seoul, Republic of Korea, ⁷Amgen Inc., Rotkreuz, Zug, Switzerland, ⁸University College London, London, England, United Kingdom
Background/Purpose: There are limited data on patients transitioning from denosumab (DMAb) to bisphosphonates (BPs). The Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531) reported that alendronate…
Abstract Number: 2657 • 2019 ACR/ARP Annual Meeting
The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study
Salman Mahmood¹, Yuanyuan Ji ², Yi Peng ² and Zaki Abou Zahr ¹, ¹Hennepin Healthcare, Minneapolis, MN, ²Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN
Background/Purpose: Bisphosphonates have been used to treat disorders of bone metabolism for several years. A common adverse reaction associated with their use constitutes a transient…
Abstract Number: 293 • 2018 ACR/ARHP Annual Meeting
Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays
Jeffrey R. Curtis¹, Rui Chen¹, Tarun Arora¹, Shanette Daigle¹, Robert Matthews¹, Huifeng Yun¹, Nicole Wright², Ayesha Jaleel³, Elizabeth Delzell⁴ and Kenneth Saag⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmngham, AL, ⁴Retired - University of Alabama at Birmingham, Birmingham, AL, ⁵UAB, Birmingham, AL
Background/Purpose: Safety concerns related to osteoporosis (OP) medication use and temporary or permanent cessation of bisphosphonate therapy (e.g. ‘drug holidays’) have generated appreciable attention in…
Abstract Number: 1256 • 2018 ACR/ARHP Annual Meeting
A Customized Health Information Technology Effectively Identifies and Directs Bone Health Services in Rural Veterans with Osteoporosis Risk Factors
Shardool Patel¹, Zachary L. Anderson¹, Grant W. Cannon², Brian C. Sauer² and Karla L. Miller², ¹Salt Lake City VA Medical Center, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Osteoporosis is underdiagnosed and undertreated in the Veterans Health Administration (VHA), especially in rural Veterans. Tools to identify risk factors in Veterans are available.…
Abstract Number: 1818 • 2018 ACR/ARHP Annual Meeting
Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Osvaldo D. Messina⁵, Jorge Morales-Torres⁶, Ronald Emkey⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aries, Argentina, ⁶Hospital Aranda de la Parra, Leon, Mexico, ⁷Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Denosumab 60 mg subcutaneously every 6 months (Q6M) increased spine and hip BMD significantly more than risedronate 5 mg orally once daily (QD) at…
Abstract Number: 2299 • 2018 ACR/ARHP Annual Meeting
Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Eric Lespessailles⁵, Jorge Malouf⁶, Bente Langdahl⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵University Hospital Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Aarhus University, Aarhus, Denmark, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: We previously demonstrated that denosumab increased lumbar spine and total hip bone mineral density (BMD) significantly more than risedronate at 12 and 24 months…
Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting
T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Felicia Cosman¹, E. Michael Lewiecki², Peter R Ebeling³, Eric Hesse⁴, Nicola Napoli⁵, Daria B Crittenden⁶, Maria Rojeski⁶, Wenjing Yang⁶, Cesar Libanati⁷ and Serge Ferrari⁸, ¹Columbia University, New York, NY, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Monash University, Melbourne, Australia, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Amgen Inc., Thousand Oaks, CA, ⁷UCB Pharma, Brussels, Belgium, ⁸Geneva University Hospital, Geneva, Switzerland
Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…
Abstract Number: 2812 • 2018 ACR/ARHP Annual Meeting
Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture
Mariana O Perez¹, Diogo S Domiciano¹, Luciene M Reis², Vanda Jorgetti² and Rosa M R Pereira¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures and subtrochanteric/diaphyseal localization that have been related to long-term bisphosphonate therapy. Patients with AFF exhibit…
Abstract Number: 48 • 2017 ACR/ARHP Annual Meeting
Modulation of Subchondral Bone Turnover Is Associated with Alteration of Cartilage Tissue Quality
Cedric Lavet, Isabelle Badoud and Patrick Ammann, Division of Bone Diseases, Geneva, Switzerland
Background/Purpose: Osteochondral unit is a bio composite responsible for an optimal distribution of load during movements and axial compression of a joint. Any alteration of…
Abstract Number: 320 • 2017 ACR/ARHP Annual Meeting
Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial
Cristiano A.F Zerbini¹, Piet Geusens², Eric Lespessailles³, Jean-Jacques Body⁴, Enrique Casado⁵, Jan Stepan⁶, David L Kendler⁷, Luis Russo⁸, Susan L. Greenspan⁹, Salvatore Minisola¹⁰, Alicia Bagur¹¹, Peter Lakatos¹², Astrid Fahrleitner-Pammer¹³, Rüdiger Möricke¹⁴, Pedro Lopez-Romero¹⁵ and Fernando Marin¹⁶, ¹Centro Paulista de Investigações Clinicas, São Paulo, Brazil, ²Maastricht University Hospital, Maastricht, Netherlands, ³Service de Rhumatologie, CHR d'Orléans, Orléans, France, ⁴CHU Brugmann, Free University Brussels, Brussels, Belgium, ⁵Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ⁶Institute of Rheumatology, Faculty of Medicine 1, Charles University, Prague, Czech Republic, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Centro de Analises e Pesquisas Clínicas LTDA,, Rio de Janeiro, Brazil, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Internal Medicine, Policlinico Umberto I,, Rome, Italy, ¹¹Centro de Osteopatías Comlit, Buenos Aires, Argentina, ¹²Department of Medicine, Semmelweis University, Budapest, Hungary, ¹³Division of Endocrinology, Medical University, Graz, Austria, ¹⁴Institut Präventive Medizin & Klinische Forschung, Magdeburg, Germany, ¹⁵Europe Research Center, Eli Lilly and Company, Madrid, Spain, ¹⁶Lilly Research Center Europe, Madrid, Spain
Background/Purpose: The VERO trial was an active-controlled fracture endpoint clinical trial that recruited postmenopausal women with low bone mass and prevalent vertebral fractures (VFx). We…
Abstract Number: 321 • 2017 ACR/ARHP Annual Meeting
A Meta-Analysis of 4 Clinical Trials of Denosumab Compared with Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates
Paul D Miller¹, N Pannacciulli², J Malouf³, A Singer⁴, E Czerwinski⁵, HG Bone⁶, C Wang², Rachel B. Wagman² and JP Brown⁷, ¹Colorado Center for Bone Research, Lakewood, CO, ²Amgen Inc., Thousand Oaks, CA, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Georgetown University Medical Center, Washington, DC, ⁵Krakow Medical Center, Krakow, Poland, ⁶Michigan Bone and Mineral Clinic, Detroit, MI, ⁷CHU de Québec Research Centre and Laval University, Québec, QC, Canada
Background/Purpose: Four clinical trials have separately shown greater BMD gains with transitioning to denosumab (DMAb) compared with continuing on bisphosphonates (BP) in subjects previously treated…
Abstract Number: 325 • 2017 ACR/ARHP Annual Meeting
Zoledronic Acid Did Not Impaired Renal Function in Patients with Osteoporosis
Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan
Background/Purpose: Bisphosphonates are recommended for patients with osteoporosis, however concerns have been raised with regards to their effect on kidney function. The aim of this…
Abstract Number: 333 • 2017 ACR/ARHP Annual Meeting
Atypical Femoral Fracture in Patients of a Rheumatology Service: Clinical, Radiographic and Bone Histomorphometric Data
Mariana O Perez¹, Diogo S Domiciano¹, Vanda Jorgetti² and Rosa M R Pereira¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures with a specific radiographic pattern and subtrochanteric / diaphyseal localization that have been related to…
Abstract Number: 828 • 2017 ACR/ARHP Annual Meeting
The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates
Jeffrey R. Curtis¹, Rui Chen², Zixu (Eric) Li², Tarun Arora², Kenneth Saag³, Nicole C. Wright⁴, Shanette Daigle², Meredith Kilgore⁵ and Elizabeth Delzell⁶, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Veterans Administration San Diego Healthcare System/UC San Diego, San Diego, CA, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, ⁶Retired - University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Given FDA warnings, drug holidays (temporary or permanent discontinuation) of bisphosphonates (BPs) after long-term (3-5 years) continuous therapy is becoming increasingly common in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].